Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is currently taking a stable dose of lipid lowering agent(s). (if applicable) or is statin naive~* Participant is currently taking a stable dose of lipid lowering agent(s). (if is at least moderate high risk for Coronary Heart Disease (CHD))~* Participant is currently taking a stable dose of lipid lowering agent(s). (if is willing to maintain Therapeutic Lifestyle Changes (TLC) / American Diabetes Association(ADA) diet)~Exclusion Criteria:~* Participant weighs less than 100 lbs (45 kg).~* Participant has hypersensitivity or intolerance to ezetimibe, or rosuvastatin or any components of these medications.~* If female, participant is pregnant or breastfeeding.~* Participant consumes more than 2 alcoholic beverages per day.~* Participant has been in a clinical trial within the last 30 days.~* Participant has heart problems such as CHF, unstable angina or heart attack.~* Participant has type 1 or 2 diabetes and has changed their medication in the last 2 months.~* Participant has liver disease.~* Participant is Human Immunodeficiency Virus (HIV) positive.~* Participant has a history of drug or alcohol abuse in the last year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin 5 mg + Ezetimibe 10 mg (Type: EXPERIMENTAL): Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
- Rosuvastatin 10 mg (Type: ACTIVE_COMPARATOR): Participants who received rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
- Rosuvastatin 10 mg + Ezetimibe 10 mg (Type: EXPERIMENTAL): Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
- Rosuvastatin 20 mg (Type: ACTIVE_COMPARATOR): Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).